Rapport Therapeutics (RAPP)

Rapport’s research is built around its RAP technology platform, which is used to identify receptor-associated proteins and related biology that may allow more targeted drug discovery. The company’s lead program, RAP-219, is an investigational small molecule being evaluated for seizure disorders and neuropsychiatric conditions. Its stated development areas include focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania.

Beyond its lead asset, Rapport is advancing earlier-stage programs involving nicotinic acetylcholine receptors, or nAChRs. These discovery programs are aimed at chronic pain and hearing disorders, broad markets where current treatment options can be limited, poorly tolerated, or insufficient for many patients.

Rapport operates in the United States and sits within the broader neuroscience biotechnology sector, a field marked by substantial unmet medical need but also high clinical and regulatory risk. Its investment case is tied to the strength of its platform, the differentiation of its compounds, clinical trial readouts, intellectual property, and the company’s ability to translate advances in neurobiology into medicines that improve outcomes for patients with complex brain and nervous system disorders.